Aurora will work on the company's 'designer' molecule sugammadex, a selective relaxant binding agent for use in anaesthesia.
Sugammadex is the newest addition to the company's anaesthesia portfolio, and is expected to launch later this year.
Aurora won the account following a competitive pitch against four undisclosed agencies. It is Organon's first PR support for the drug.
The brief includes a UK-wide programme of media relations and medical education aimed at anaesthetists who will use the product.
The account will be headed up by Aurora co-founder and joint MD Neil Crump.
Sugammadex reverses the action of Organon's Neuromuscular blocking agent Esmeron.
Neuromuscular block is given to patients undergoing surgery to paralyse them, creating better conditions for the surgeon to operate.
Sugammadex reverses Esmeron rapidly so patients can be brought around more quickly following surgery.
The account follows the appointment of Sian Hurst as Aurora's associate director (PRWeek, 29 February)